Search
dasabuvir
Indications:
- hepatitis C infection genotype 1*
* including patients with cirrhosis
Dosage:
- one tablet twice a day
- used in combination with ombitasvir/paritaprevir/ritonavir (Viekira Pak)
Mechanism of action:
- non-nucleoside RNA polymerase inhibitor
General
antiviral agent
enzyme inhibitor
References
- Orciari Herman A and Sofair A
Viekira Pak Approved for Hepatitis C
Physician's First Watch, Dec 22, 2014
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA News Release. Dec 19, 2014
FDA approves Viekira Pak to treat hepatitis C
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm
Component-of
dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR)